证券代码：301087 证券简称：可孚医疗 公告编号：2025-069 可孚医疗科技股份有限公司 2025年第三次临时股东会决议公告 3、会议召开方式：采取现场投票与网络投票相结合的方式 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开时间： （1）现场会议召开时间：2025 年 9 月 10 日（星期三）15:00； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 10 日的交易时间，即 9:15 - 9:25，9:30 - 11:30 和 13:00 - 15:00；通 过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025 年 9 月 10 日 9:15 - 15:00。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、现场会议召开地点：长沙市雨花区万家丽中路一段 426 号高桥大健康医 药城 8 楼 801 会议室。 特别提示： 1、本次股东会未出现否决议案的情形。 4、会议召集人：公司董事会 （1）股东出席会议 ...

可孚医疗科技股份有限公司 章 程 （草案） （H 股发行并上市后适用） 2025年9月 1 | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股份 | 5 | | 第一节 | 股份发行 | 5 | | 第二节 | 股份增减和回购 | 7 | | 第三节 | 股份转让 | 8 | | 第四章 | 股东和股东会 | 9 | | 第一节 | 股东 | 9 | | 第二节 | 控股股东和实际控制人 | 12 | | 第三节 | 股东会的一般规定 | 14 | | 第四节 | 股东会的召集 | 18 | | 第五节 | 股东会的提案与通知 | 19 | | 第六节 | 股东会的召开 | 21 | | 第七节 | 股东会的表决和决议 | 24 | | 第五章 | 董事和董事会 | 28 | | 第一节 | 董事 | 28 | | 第二节 | 董事会 | 32 | | 第三节 | 独立董事 | 37 | | 第四节 | 董事会专门委员会 | 40 | | 第六章 | 总裁及其他高级管理人员 | 42 | | 第七章 | 财务会计制度、利润分 ...

Group 1 - The company, KeFu Medical (301087), expressed an open attitude towards collaborating with outstanding domestic enterprises to promote the development and application of AI medical technology [1] - As of now, the company has not established a direct cooperation relationship with Huawei in the field of AI medical technology [1]

长沙晚报全媒体记者 曹开阳 实习生 彭傲 金秋时节成为长沙上市公司新的起点。继蓝思科技成功登陆香港联交所后，近期又有两家长沙A股上市公司—— 军信股份和可孚医疗先后发布公告，向香港联交所递交境外上市外资股（H股）发行与上市申请并刊发申请资 料。 这两家长沙上市企业的情况如何？它们为什么又会在A股上市后不约而同地选择"A+H"模式？成功赴港上市又将 给它们带来怎样的影响？记者进行了多方采访。 两家企业提出赴港上市申请 为加速国际化进程，拓宽融资渠道，提升国际影响力，军信股份启动H股上市筹备。8月14日，军信股份发布公告 称，其已于8月13日向香港联交所递交了发行境外上市外资股（H股）股票并在香港联交所主板挂牌上市的申请， 且同日在香港联交所网站刊登了本次发行的申请资料。若成功上市，军信股份有望成为国内第一家"A+H"环保民 营上市公司。 行业头部企业的"底气"选择 事实上，对于长沙上市企业来说，"A+H"已有先例，2000年10月12日在深交所主板上市的中联重科，其后在2010 年12月23日成功登陆香港联交所。今年7月9日，已先期在深交所创业板上市的蓝思科技在香港联交所上市，至 此，当前湘股板块中"A+H"模 ...

Core Viewpoint - The company has not established a direct partnership with Huawei in the AI medical field, despite its openness to collaboration with leading domestic enterprises to promote the development and application of AI medical technology [1]. Company Summary - The company, KeFu Medical (301087.SZ), expressed its willingness to collaborate with outstanding domestic companies to advance AI medical technology [1]. - As of now, there is no direct cooperation between the company and Huawei in the AI medical sector [1].

Group 1 - The company, Kefo Medical, announced an investment in Newlink Medical, focusing on implantable brain-machine interface technology to develop bionic eyes and ears [1] - This investment is expected to create strategic synergy with the company's existing hearing business, particularly in addressing congenital hearing loss [1]

（编辑 袁冠琳） 证券日报网讯 可孚医疗9月8日在互动平台回答投资者提问时表示，作为一家全生命周期个人健康管理 企业，公司产品覆盖康复辅具、医疗护理、健康监测、呼吸支持及中医理疗五大领域，能够为消费者提 供一站式解决方案。在老年人及失能人员护理方面，公司产品涵盖助听器、轮椅、护理床、助行器等康 复辅具产品，制氧机、呼吸机等呼吸支持设备，以及防褥疮垫、成人纸尿裤等医用护理产品，公司积极 探索与各方合作，构建健康养老服务生态。 ...

Group 1 - The core point of the article is that Kefu Medical (301087) has approximately 19,000 total shareholders as of August 29, 2025 [1]

雷递网 雷建平 9月7日 招股书显示，可孚医疗2022年、2023年、2024年营收分别为29.77亿元、28.54亿元、29.83亿元；毛利分别为11.27亿元、11.73亿元、15亿元；期内盈利分 别为3亿元、2.53亿元、3.12亿元。 | | | 截至12月31日止年度 | | 截至6月30日止六個月 | | | --- | --- | --- | --- | --- | --- | | | 2022年 | 2023年 | 2024年 | 2024年 | 2025年 | | | 人民幣千元 | 人民幣千元 | 人民幣千元 | 人民幣千元 | 人民幣千元 | | | | | | (未經審核) | | | 收入 | 2.976.958 | 2.853.695 | 2,982,931 | 1.558.610 | 1.495.764 | | 銷售成本 | (1.850.419) | (1,681,144) | (1,474,227) | (798,314) | (747,987) | | 毛利 | 1.126.539 | 1,172,551 | 1.508.704 | 760,296 | 747.777 | ...

Core Viewpoint - Company Kefu Medical has submitted an application for listing on the Hong Kong Stock Exchange, aiming for a dual listing after its previous listing on the Shenzhen Stock Exchange in 2021 [3][4]. Company Overview - Kefu Medical is one of the largest home medical device companies in China, established in 2007, focusing on providing convenient solutions for consumers and patients seeking high-quality home medical devices [3][5]. - The company has significant competitive advantages in various verticals of the home medical device industry, ranking second among all home medical device companies in China based on projected domestic revenue for 2024 [3][5]. Financial Performance - For the six months ending June 30, 2025, Kefu Medical reported revenue of approximately 1.496 billion RMB, a year-on-year decrease of about 4.0%, and a net profit attributable to shareholders of approximately 167 million RMB, down 9.5% year-on-year [3][4][14]. Fundraising Purpose - The net proceeds from the IPO are intended for global expansion, ongoing product research and technological innovation, including applications of artificial intelligence and the Internet of Things, expanding domestic sales channels and distribution networks, brand promotion, and general corporate purposes [4][5]. Product Strategy - Kefu Medical strategically focuses on five categories of home medical devices with strong growth potential: rehabilitation aids, medical care products, traditional Chinese medicine therapy products, health monitoring products, and respiratory support products [6][16]. - The company offers a comprehensive product range with over 200 products and thousands of specifications, enhancing its position as a one-stop solution for consumers' medical needs [6][16]. Sales Network - Kefu Medical has developed a broad and deep sales network in China, with significant overseas influence, covering both online and offline channels [7][9]. - The online sales revenue reached 1.9807 billion RMB in 2024, with full coverage of major e-commerce platforms such as Tmall, JD.com, Douyin, Xiaohongshu, Pinduoduo, and Yaoshi Bang [10][11]. Market Position - According to Frost & Sullivan, Kefu Medical ranks first in the online revenue segment of the home medical device market in China for 2024 [11][12]. - The company has expanded its global footprint, reaching over 60 countries and regions across Asia, Africa, Europe, and the Americas [13].